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300 The Journal of Thoracic and CardioBackground: Recent consensus statements recommend cardiac enzyme release as
the essential criterion for diagnosing myocardial infarction. However, the outcome
implications of cardiac enzyme release in patients undergoing coronary artery
bypass grafting are controversial.
Methods: Eight hundred patients were followed for 30 days after elective on-pump
coronary artery bypass grafting in a multicenter, prospective, randomized trial of the
anti-C5 complement antibody pexelizumab. Data from centralized electrocardiog-
raphy and creatine kinase MB analyses were examined for any association with
death or severe left ventricular dysfunction.
Results: More than half of the 800 patients had peak creatine kinase MB levels of
more than 5 times the upper limit of 5 ng/mL set by the core laboratory. The median
peak value was 29 ng/mL. The incidence of the combined outcome (death or severe
left ventricular dysfunction) was 1.7% if the peak creatine kinase MB level was less
than 25 ng/mL and 18.0% if 100 ng/mL or greater (P  .01). Similarly, the
incidence of new Q-wave myocardial infarction was 3.9% if the peak creatine kinase
MB level was less than 25 ng/mL and 30.6% if 100 ng/mL or greater (P  .01). In
a multivariate analysis that included preoperative and intraoperative factors, as well
as peak enzyme release and Q-wave myocardial infarction, the strongest predictor
of the combined outcome was a peak creatine kinase MB level of 100 ng/mL or
greater. New Q-wave myocardial infarction did not significantly predict the com-
bined outcome.
Conclusions: Increased postoperative peak creatine kinase MB level, especially when
20 times or more of the upper limit of normal, indicates increased risk of severe
postoperative left ventricular dysfunction and mortality within 30 days of coronary
artery bypass grafting. High peak enzyme level is a stronger predictor of adverse
outcomes than is postoperative Q-wave myocardial infarction in this population.
Methods of diagnosing myocardial infarctions (MIs) and theirprognostic significance after coronary artery bypass surgery(CABG) have been controversial for 3 decades. Depending onthe diagnostic criteria, the reported incidence of MI duringCABG ranges from 4% to 80%.1 New Q waves on theelectrocardiogram (ECG), once considered the best available
predictor of outcome after CABG, have been variously reported as significant2,3 or
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controversy exists partly because ECG changes occur in the
majority of patients undergoing CABG, making the signif-
icance of these changes difficult to interpret. Myocardial
enzyme release, another potential marker of MI, is similarly
common in patients undergoing CABG. However, study of
the outcome implications of enzyme release in the CABG
population has only recently begun, and there is substantial
room for refinement.
Two consensus statements by cardiology groups have
recommended the use of biochemical markers as the essen-
tial criterion for diagnosis of acute MI.6,7 Both statements
include MI after CABG in this recommendation but cite
little supporting evidence and state the need for more data.
Since the publication of the consensus statements, reports
from 2 prospective perioperative studies addressing this
issue have appeared, one of 496 patients randomized to
CABG in a study of angioplasty versus CABG surgery8 and
another of 2394 patients randomized to CABG in a study of
the Na/H exchange inhibitor cariporide.9 Both reports
note statistically significant increases in the risk of death
after discharge when peak myocardium-specific creatine
kinase (CK) MB isoenzyme levels are greater than 5 times
the upper limit of normal. Limitations of these reports
include the absence of ECG data from the first8 and the
absence of central laboratory enzyme analysis from the
second.9 Here we report data collected from 800 patients
undergoing CABG in a study of the humanized monoclonal
antibody pexelizumab, which blocks activation of C5 com-
plement. The results of centralized ECG analysis and central
laboratory enzyme analysis are presented.
Methods
Patients
The study sample consisted of patients who underwent CABG with
cardiopulmonary bypass (CPB) in 1999 and 2000 at one of 65 centers
in the United States. These patients were enrolled in a prospective,
multicenter, randomized, double-blind, placebo-controlled phase II
trial of pexelizumab, a novel single-chain fragment of a humanized
monoclonal antibody against complement component C5.10 This
study was approved by the institutional review board of each partic-
ipating institution, and informed consent was obtained from all pa-
tients.
Patients were included in the study if they had any of the
following risk factors for myocardial necrosis: age of 60 years or
greater, previous CABG, history of congestive heart failure (New
York Heart Association class III or IV), history of more than 2
MIs, an MI within 14 days of screening, history of cerebrovascular
disease (cerebrovascular accident, transient ischemic attack, and/or
carotid endarterectomy), or a current serum creatinine level of 1.3
mg/dL or greater but less than 2.0 mg/dL. Exclusion criteria
included active infection or malignancy, uncontrolled diabetes,
hepatic disease, preoperative intra-aortic balloon pump or left
ventricular (LV) assist device, cardiogenic shock, recent (within
72 hours) percutaneous angioplasty failure, presence of a ventric-
The Journal of Thoraciular pacemaker, or complete left bundle branch block on a 12-lead
ECG.
Nine hundred fourteen patients were enrolled in the primary
study. For this substudy of cardiac enzyme release, patients who
underwent combined CABG and valve surgery (n  114) were
excluded, leaving 800 patients undergoing isolated CABG in the
present study. Patients were randomized to 1 of 3 treatments: (1)
placebo, (2) a 2.0 mg/kg bolus of pexelizumab after induction of
general anesthesia, or (3) a 2.0 mg/kg bolus of pexelizumab
followed by a continuous infusion of 0.05 mg · kg1 · h1 for 24
hours. Although the conduct of the anesthesia and surgical inter-
vention was similar for each institution, no attempts were made to
standardize techniques. Aortic crossclamping with cardioplegic
arrest and CPB using hemodilution, mild-to-moderate hypother-
mia, and membrane oxygenators were used at all institutions.
Data Collection
CK-MB levels were measured at a centralized core laboratory
facility (Q-LABS, Atlanta, Ga) by using standard techniques. The
upper limit of the normal range for this analysis is 5 ng/mL. Blood
samples were acquired preoperatively (baseline) and postopera-
tively at 4, 8, 16, 20, 24, 30, and 36 hours after release of the aortic
crossclamp and on postoperative days 2, 4, 7, and 30. All bioana-
lytic and CK-MB assays were validated according to International
Conference on Harmonisation guidelines. Although pexelizumab
is nonreactive with any other non-C5-complement human tissue or
TABLE 1. Demographic and perioperative data for all pa-
tients (n  800)
Age, y (mean  SD) 67  9
Weight, kg (mean  SD) 85  15
Sex
Male 612 (76.5)
Female 188 (23.5)
Diabetes (type 1 or 2) 274 (34.2)
Congestive heart failure 132 (16.5)
Peripheral vascular disease 147 (18.4)
Hypertension 627 (78.4)
Tobacco use 291 (36.4)
Chronic obstructive
pulmonary disease
12 (1.5)
Previous MI 393 (49.1)
Renal insufficiency 147 (18.4)
Saphenous vein graft 718 (89.8)
Internal mammary artery
graft
745 (93.1)
Complete revascularization 762 (95.2)
CPB time, min (mean 
SD)
94  36
Aortic crossclamp time, min
(mean  SD)
64  26
History of neurologic event 121 (15.1)
Previous CABG 63 (7.9)
Data are presented as the number of patients (%) unless otherwise
specified. MI, Myocardial infarction; CPB, cardiopulmonary bypass; CABG,
coronary artery bypass grafting.other species complement, the Abbott Axsym CK-MB assay that
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reagent and washing steps to prevent any possible interference.
ECGs were obtained preoperatively, on intensive care unit
admission, and on postoperative days 1, 4, 7, and 30. A blinded
and independent core laboratory (Ischemia Research and Educa-
tion Foundation, San Francisco, Calif) analyzed ECG records to
determine postoperative Q-wave MI according to Minnesota
code.11
Statistical Analysis
Analyses were performed to examine the relationship between
peak CK-MB release and 30-day mortality or severe LV dysfunc-
tion (defined as use of 4 inotropic drugs, LV assist device, or
intra-aortic balloon pump). The area under the curve (AUC) for
CK-MB release was determined with the linear trapezoidal method
by using each patient’s available data (with linear interpolation for
missing intermediate time points). The relationship between AUC
and peak CK-MB level was explored with Spearman rank corre-
lation. Patients were then grouped by CK-MB level, and contin-
gency table analysis and 2 tests were used to compare event rates
across these groups. The Cochran-Mantel-Haenszel trend test was
used to check for any association between peak levels of CK-MB
and new Q waves on the postoperative ECG.
Univariate and multiple logistic regression were used to con-
struct a model of the association between perioperative variables
and the risk of 30-day mortality or severe LV dysfunction, as
Figure 1. Relationship between AUC for postoperative
postoperative CK-MB level (nanograms per milliliter).defined above. Univariate logistic regression analysis was per-
302 The Journal of Thoracic and Cardiovascular Surgery ● Febrformed on each of several candidate variables. If the subsequent P
value was less than .15, then the variable was included in an initial
multiple logistic regression model. Variables were omitted from
the final multiple regression model if their P value in the initial
model was greater than .10.
Results
Demographic and Perioperative Data
Preoperative patient characteristics and intraoperative data
(Table 1) were similar across the 3 study groups, and there
were no differences between groups in the rate of the
primary composite endpoint of death, MI, ventricular dys-
function, and central neurologic deficit.10 A post hoc anal-
ysis demonstrated that patients who received a bolus injec-
tion plus subsequent infusion of the C5 complement
inhibitor had a lower risk of the composite endpoint of
CK-MB of 100 ng/mL or greater or death within 30 days of
CABG than did placebo or bolus-only patients.10
CK-MB Release
For the remaining analyses, patients in all 3 study groups
were combined into a single 800-patient cohort. AUC and
peak CK-MB values in this cohort showed a very strong
linear relationship (Spearman r  0.9; P  .005; Figure 1).
Consequently, the peak CK-MB value was used in all sub-
B release (hours * nanograms per milliliter) and peakCK-Msequent analyses.
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half (438/785 [55.6%]) had peak CK-MB levels of greater than
5 times the upper limit of 5 ng/mL set by the core laboratory
(Figure 2). The median peak enzyme value for the entire cohort
of patients was 29 ng/mL. Peak levels occurred 4 hours after
release of the aortic crossclamp in 55% of patients, 8 hours in
19%, 16 hours in 12%, and 20 hours in 6%.
CK-MB Release and Adverse Outcomes
Trend tests revealed a significant association between post-
operative peak CK-MB levels and mortality at 30 days,
severe LV dysfunction, and the combination of these out-
comes (Table 2). Although there is a modest increase in the
incidence of these adverse outcomes for peak CK-MB lev-
els between 25 and 49 ng/mL (5-10 times the upper limit of
Figure 2. Distribution of peak postopera
TABLE 2. Incidence of clinical adverse outcomes and Q-
CK-MB level
Peak postop
0-24 25-49
Death 3/345 (0.9) 2/278 (0.7)
LVD 3/343 (0.9) 11/277 (4.0)
Death or LVD 6/345 (1.7) 13/278 (4.7)
Q-wave MI* 13/335 (3.9) 10/270 (3.7)
Data are presented as proportion of patients with outcome (%). CK-MB, C
*Twenty-three patients had electrocardiogram data that were incompletenormal) and those between 50 and 99 ng/mL (10-20 times
The Journal of Thoracithe upper limit of normal), the increase is markedly greater
for peak CK-MB levels of 100 ng/mL or greater. Further-
more, higher peak CK-MB levels were associated with a
greater likelihood of the development of new Q-wave MI on
the postoperative ECG (Table 2).
Other Predictors of Adverse Outcomes
Significant predictors of 30-day mortality or severe LV
dysfunction in the univariate analyses were previous
CABG, CPB time, crossclamp time, Q-wave MI, and peak
CK-MB level of 100 ng/mL or greater (Table 3). When
multivariate analysis was performed on all univariate pre-
dictors of mortality–LV dysfunction with P values of less
than .15, new Q-wave MI did not contribute to the final
K-MB levels (nanograms per milliliter).
e myocardial infarction according to peak postoperative
ve CK-MB (ng/mL)
P value50-99 >100
1/112 (0.9) 3/50 (6.0) .04
5/112 (4.5) 8/50 (16.0) .01
6/112 (5.4) 9/50 (18.0) .01
10/108 (9.3) 15/49 (30.6) .01
e kinase MB; LVD, left ventricular dysfunction; MI, myocardial infarction.
t interpretable.wav
erati
reatinmodel (Table 4).
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This analysis provides evidence that a highly increased
postoperative serum CK-MB level is a strong independent
predictor of severe adverse outcome after CABG. The risk
of 30-day mortality or severe LV dysfunction was 18% for
patients with peak CK-MB levels of 100 ng/mL or greater
or 20 or more times the upper limit of normal. However,
only 30.6% of these patients had new Q-wave MI, suggest-
ing that non-Q-wave MI accounts for the majority of MIs
associated with adverse outcome. Furthermore, in a multi-
variate analysis that included both Q-wave MI and peak
CK-MB value as predictors, we found that new Q-wave MI
was not an independent predictor of 30-day mortality or
severe LV dysfunction. These data contradict the notion that
increased postoperative CK-MB levels have less clinical
utility than new Q-wave MI. Our data confirm the results of
TABLE 3. Risk of adverse outcome (30-day mortality or
early severe left ventricular dysfunction) associated with
patient and perioperative factors
Variable Odds ratio 95% CI P value
History of MI 1.06 0.50-2.29 .89
History of CHF 1.80 0.67-4.78 .24
History of neurologic
event
1.17 0.48-2.88 .73
Previous CABG 3.16 1.32-7.57 .01
Diabetes 1.87 0.95-3.68 .07
Increased creatinine 1.57 0.72-3.43 .26
Age 1.03 0.99-1.08 .14
CPB time 1.02 1.01-1.03 .01
Crossclamp time 1.02 1.00-1.03 .01
Q-wave MI 3.48 1.37-8.86 .01
Peak CK-MB 100 ng/mL 6.23 2.73-14.22 .01
CI, Confidence interval; MI, myocardial infarction; CHF, congestive heart
failure; CABG, coronary artery bypass grafting; CPB, cardiopulmonary
bypass.
TABLE 4. Multiple logistic regression model to predict
adverse outcome (30-day mortality or early severe left
ventricular dysfunction)
Variable Odds ratio 95% CI P value
Previous CABG 2.59 0.92-7.27 .07
Diabetes 2.05 0.98-4.29 .06
Age 1.05 1.00-1.10 .04
CPB time 1.02 1.01-1.04 .01
Peak CK-MB 100 ng/mL 3.04 1.14-8.09 .03
Q-wave MI 2.20 0.71-6.79 .17
Crossclamp time 0.98 0.96-1.00 .10
Table includes all variables with univariate P values of less than .15.
CI, Confidence interval; CABG, coronary artery bypass grafting; CPB,
cardiopulmonary bypass; MI, myocardial infarction.2 other recent studies,8,9 which found that postoperative
304 The Journal of Thoracic and Cardiovascular Surgery ● Febrserum CK-MB levels in patients undergoing CABG are
independently associated with adverse outcome.
Generalization of Results
The patient sample used in the present study consisted of
800 patients undergoing isolated CABG surgery at 65 cen-
ters throughout the United States in 1999 and 2000. This
patient sample is most likely representative of the current
surgical population of patients undergoing CABG with CPB
for the first time. However, our results might not apply to
patients who undergo off-pump CABG (OPCAB). Other
randomized studies comparing CABG with CPB to OPCAB
have demonstrated significantly less CK-MB release12,13 or
troponin T release14 with the latter technique, but the reports
provide no information regarding any relationship between
these markers of myocardial ischemia and rates of mortality
or severe LV dysfunction. Therefore, it is unclear whether
peak CK-MB release predicts adverse outcomes in patients
undergoing OPCAB as consistently as it does in patients
who undergo CABG with CPB.
Prognostic Significance of CK-MB Release
Skeletal muscles and atrial tissue both contain CK-MB.15,16
Trauma to these tissues and manipulation of the heart during
CABG might induce at least some of the CK-MB release seen
in these patients. Although the majority of our patients released
CK-MB at levels that would indicate significant myocardial
necrosis in a nonsurgical population, most did not have severe
adverse cardiac outcomes, even when the peak enzyme level
was up to 5 times the upper limit of normal. Similarly, in the
cohort study of 99 patients undergoing on-pump CABG re-
cently reported by Puskas and colleagues,13 the mean CK-MB
level at 8 hours postoperatively was approximately 23 ng/mL
(4 times the upper limit of normal), yet 30-day mortality was
only 2%. Therefore, these seemingly high levels of enzyme
release (up to 5 times the upper limit of normal) might repre-
sent surgically associated nonischemic damage, relatively
small areas of ischemia, or ischemia-reperfusion–mediated
myocardial necrosis.
Long-term follow-up studies by Costa and coworkers8
and Klatte and associates9 have shown that patients with
peak CK-MB release of less than 5 times the upper limit of
normal continue to have a relatively low risk of mortality
after the first 30 postoperative days. Costa and coworkers8
found 1-year mortality rates of 1.1%, 0.5%, 5.4%, and
10.5% for patients with peak CK-MB release of 1 or less, 1
to 3, 3 to 5, and greater than 5 times the upper limit of
normal, respectively. Similarly, Klatte and associates9
found 6-month mortality rates of 3.4%, 5.8%, 7.8%, and
20.2% in patients with peak enzyme levels of less than 5, 5
to 10, 10 to 20, and 20 or more times the upper limit of
normal, respectively. When combined with the results of the
present study, these data from more than 4000 patients
uary 2005
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ica and Europe clearly demonstrate that the risk of short-
and long-term mortality and other adverse outcomes in-
creases as peak postoperative CK-MB levels increase.
These data do not necessarily support the concept of a single
critical level of peak enzyme release that is diagnostic for
MI; rather, they suggest that the higher the peak level, the
worse the prognosis. Mortality is especially high in patients
with peak CK-MB levels of 20 or more times the upper limit
of normal. In all 3 studies, peak CK-MB level was the
strongest single predictor of adverse outcomes.
CK-MB Versus Troponins
Currently, the preferred biochemical markers for myocar-
dial damage in the nonsurgical setting are cardiac troponins
I and T.7,17 These enzymes are more cardiac specific than
CK-MB because skeletal muscle does not contain either
troponin I or T in significant quantities. In addition, plasma
levels of the troponins remain at their peak for a longer
period after myocardial damage than do CK-MB levels,
making peak levels easier to determine. A few reports
suggest that troponin levels are as accurate as, or even more
accurate than, CK-MB levels in detecting MI (as determined
by other indirect markers) in cardiac surgical patients.18-20
However, lack of power, insufficient follow-up, and other
limitations prevent these studies from providing a clear
estimate of the predictive value of troponins for post-CABG
adverse events. In contrast, there are decades of robust data
documenting the clinical specificity of CK-MB for irrevers-
ible cardiac tissue damage.7 It seems likely, however, that
future studies with larger cohorts and longer follow-up will
show higher troponin levels to be associated with increased
risk of mortality and other adverse cardiac outcomes in
patients undergoing CABG, just as with higher CK-MB
levels. Furthermore, because troponins remain at their peak
levels far longer than the CK-MB isoenzyme, fewer samples
might be needed to estimate risk after CABG.
Relationship of ECG Findings to Peak CK-MB Level
We found a significant association between the incidence of
new Q-wave MI and higher peak levels of CK-MB in that
nearly one third of the patients with peak CK-MB levels of
100 ng/mL or greater had new Q-wave MI. However, al-
though new Q-wave MI was a significant univariate predic-
tor of 30-day mortality or severe LV dysfunction, this
relationship was not sustained in the final multivariate
model. Klatte and associates9 also found a significant uni-
variate association between new Q-wave MI and 6-month
mortality that fell out of the final model when multivariate
analysis was performed. Thus the predictive power of peak
postoperative CK-MB for post-CABG adverse outcomes
predominates over that of new Q-wave MI when both
factors are included in multivariate outcome analysis.
The Journal of ThoraciFindings from other studies also call into question the
independent predictive value of new postoperative Q-wave
MI. A detailed analysis and follow-up of new inferior Q-
wave infarctions reported in the Emory Angioplasty versus
Surgery Trial21 demonstrated that 10 of 11 patients coded
for such MIs had normal ejection fractions, no regional wall
motion abnormalities, and patent grafts. Additionally, in
194 patients randomized to CABG surgery who were fol-
lowed for 3 years, the mortality rate did not differ between
patients with or without new Q waves (5% vs 6.5%, respec-
tively).22 Furthermore, Klatte and associates9 found that
patients who experienced peak CK-MB levels of less than 5
times the upper limit of normal had similar 6-month mor-
tality rates irrespective of whether they had new Q-wave MI
(2.6%) or not (3.6%). Finally, postoperative rhythm distur-
bances, pacing, and pericardial inflammation commonly
interfere with ECG interpretation, and new Q waves have
been found in some patients to reflect unmasking of old
MIs.23 Although these data do not necessarily negate earlier
findings that new Q-wave MI predicts adverse outcome
after CABG,4,5 they clearly reinforce our evidence that new
Q-wave MIs have little clinical significance when they
coincide with low levels of CK-MB release. Alternatively,
increased enzyme levels are likely to be of great importance
irrespective of whether they are accompanied by new Q-
wave MI.
Potential Limitations
Although we believe our patient sample, together with those
described by Costa and coworkers8 and Klatte and associ-
ates9 is representative of the current population of patients
undergoing on-pump CABG, we acknowledge that all 3
studies involved patients enrolled in clinical trials, mostly at
academic institutions. The overall population of patients
with CABG might differ from this cohort in some ways; for
example, they might be at lower risk for adverse outcomes.
Also, the small number of adverse events might have lim-
ited the extent to which we can draw conclusions regarding
the clinical significance of CK-MB increase to 5 to 10 times
the upper limit of normal. Furthermore, as mentioned
above, patients undergoing OPCAB were not included, and
such patients generally release lower levels of CK-MB than
what we observed. Additionally, our multivariate analysis
included only those factors available in the database of the
primary study, so that some factors that have an effect on
prognosis might not have been examined. Finally, our out-
come data were limited to the first 30 days after the oper-
ation; ideally, follow-up would have been longer. However,
data from the 2 other large trials suggest that our primary
finding, the increased risk associated with higher peak
CK-MB levels, remains valid well beyond the 30-day post-
operative period.
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Our findings provide robust support for the use of peak
postoperative CK-MB as an independent prognostic marker
for adverse outcome in patients undergoing CABG. Further-
more, peak enzyme level is a much stronger predictor of
death or LV dysfunction than is the appearance of new
Q-wave MI on the ECG, especially when the new Q-wave
MI is not accompanied by a substantial CK-MB increase.
Because the peak might occur early or late in the postop-
erative period, it is probably necessary to measure this
enzyme more than once during the first 24 hours after the
operation. However, AUC calculation does not appear nec-
essary. In the clinical trial setting, peak CK-MB level might
be the best measure of the effectiveness of new drugs or
other treatments intended to reduce the effects of CABG-
related ischemia-reperfusion injury and the inflammatory
response to CABG and CPB. Further study is required to
determine whether troponin levels are superior to CK-MB
levels in this regard. Peak CK-MB level is an effective way
to identify high-risk post-CABG patients and thus permit
aggressive triage and treatment to reduce the high incidence
of adverse outcomes in the long term. Future studies should
examine the value of specific interventions when their use is
determined by postoperative CK-MB levels.
We thank Stephen N. Palmer, PhD, for his invaluable contri-
butions to the writing of this article.
References
1. Jain U. Myocardial infarction during coronary artery bypass surgery.
J Cardiothorac Vasc Anesth. 1992;6:612-23.
2. Chaitman BR, Alderman EL, Sheffield LT, et al. Use of survival
analysis to determine the clinical significance of new Q waves after
coronary bypass surgery. Circulation. 1983;67:302-9.
3. Force T, Hibberd P, Weeks G, et al. Perioperative myocardial infarc-
tion after coronary artery bypass surgery: clinical significance and
approach to risk stratification. Circulation. 1990;82:903-12.
4. Gardner MJ, Johnstone DE, Lalonde L. Perioperative myocardial
infarction with coronary artery surgery: diagnosis, incidence and con-
sequences. Can J Cardiol. 1987;3:336-41.
5. Roberts AJ, Spies SM, Lichtenthal PR, et al. Change in left ventricular
performance related to perioperative myocardial infarction in coronary
artery bypass graft surgery. Ann Thorac Surg. 1983;35:516-24.
6. Califf RM, Abedelmeguid AE, Kuntz RE, et al. Myonecrosis after
revascularization procedures. J Am Coll Cardiol. 1998;31:241-51.
7. Alpert JS, Antman E, Apple F, et al. Myocardial infarction redefined:
a consensus document of the joint European Society of Cardiology/
American College of Cardiology committee for the redefinition of
myocardial infarction. J Am Coll Cardiol. 2000;36:959-69.
306 The Journal of Thoracic and Cardiovascular Surgery ● Febr8. Costa MA, Carere RG, Lichtenstein SV, et al. Incidence, predictors,
and significance of abnormal cardiac enzyme rise in patients treated
with bypass surgery in the arterial revascularization therapies study
(ARTS). Circulation. 2001;104:2689-93.
9. Klatte K, Chaitman BR, Theroux P, et al. Increased mortality after
coronary artery bypass surgery is associated with increased levels of
postoperative creatine kinase-myocardial band isoenzyme release.
J Am Coll Cardiol. 2001;38:1070-7.
10. Shernan SK, Fitch JCK, Nussmeier NA, et al. Impact of pexelizumab,
a recombinant, humanized, single-chain, anti-C5 complement anti-
body, on total mortality and adverse cardiovascular outcomes in car-
diac surgical patients undergoing cardiopulmonary bypass. Ann Tho-
rac Surg. 2004;77:942-50.
11. Chaitman B, Zhou S, Tamesis B, et al. Methodology of serial ECG
classification using a Minnesota code adaptation of the NOVACODE
for Q-wave myocardial infarction in the Bypass Angioplasty Revas-
cularization Investigation (BARI). J Electrocardiol. 1996;29:265-77.
12. van Dijk D, Nierich AP, Jansen EW, et al. Early outcome after
off-pump vs on-pump coronary artery bypass surgery: results from a
randomized study. Circulation. 2001;104:1761-6.
13. Puskas JD, Williams WH, Duke PG, et al. Off-pump coronary artery
bypass grafting provides complete revascularization with reduced
myocardial injury, transfusion requirements, and length of stay: a
prospective randomized comparison of two hundred unselected pa-
tients undergoing off-pump versus conventional coronary artery by-
pass grafting. J Thorac Cardiovasc Surg. 2003;125:797-808.
14. Khan NE, De Souza A, Mister R, et al. A randomized comparison of
off-pump and on-pump multivessel coronary-artery bypass surgery.
N Engl J Med. 2004;350:21-8.
15. Tsung JS, Tsung SS. Creatine kinase isoenzymes in extracts of various
human skeletal muscles. Clin Chem. 1986;32:1568-70.
16. Graeber GM, Cafferty PJ, Wolf RE, et al. Creatine kinase and lactate
dehydrogenase in the muscles encountered during median sternotomy
and in the myocardium of the cardiac chambers. J Thorac Cardiovasc
Surg. 1985;89:700-5.
17. Jaffe AS, Ravkilde J, Robert R, et al. It’s time for a change to a
troponin standard. Circulation. 2000;102:1216-20.
18. Greenson N, Macoviak J, Krishnaswamy P, et al. Usefulness of cardiac
troponin I in patients undergoing open heart surgery. Am Heart J.
2001;141:447-55.
19. Benoit M-O, Paris M, Silleran J, et al. Cardiac troponin I: its contri-
bution to the diagnosis of perioperative myocardial infarction and
various complications of cardiac surgery. Crit Care Med. 2001;29:
1880-6.
20. Holmvang L, Jurlander B, Rasmussen C, et al. Use of biochemical
markers of infarction for diagnosing perioperative myocardial infarc-
tion and early graft occlusion after coronary artery bypass surgery.
Chest. 2002;121:103-11.
21. King SB, Lembo NJ, Weintraub WS, et al. A randomized trial com-
paring coronary angioplasty with coronary bypass surgery. Emory
Angioplasty versus Surgery Trial (EAST). N Engl J Med. 1994;331:
1044-50.
22. Hodakowski GT, Craver JM, Jones EL, King SB, Guyton RA. Clinical
significance of perioperative Q wave myocardial infarction: the Emory
angioplasty versus surgery trial. J Thorac Cardiovasc Surg. 1996;112:
1447-54.
23. Bassan M, Oatfield R, Hoffman I, Matloff J, Swan H. New Q waves
after aortocoronary bypass surgery: unmasking of an old infarction.
N Engl J Med. 1974;290:349-53.
uary 2005
Appendix
Pexelizumab Study Investigators
Robert Albus, Inova Fairfax Hospital
Keith Allen, St Vincent’s Medical Center
Gabriel S. Aldea, Richard Anderson, University of Washington,
School of Medicine
John Armitage, Mary Washington Hospital
Clinton Baisden, Scott and White Memorial Hospital
Daniel Beckman, Richard Kovacs, Methodist Research Institute
Elliott Bennett-Guerrero, Columbia University College of Physi-
cians & Surgeons
Stuart Boe, North Ridge Medical Center
Michael Borkon, Mid-America Heart Institute (St Luke’s)
Steven Boyce, Washington Hospital
John H. Braxton, Maine Medical Center
Clay Burnett, Memorial Medical Center, Inc
Paul Burns, Sinai Hospital
John C. Chen, Hawaii Kaiser Permanente
Richard P. Cochran, Robert Love, University of Wisconsin Hos-
pitals and Clinics and William S. Middleton V.A. Hospital
Thomas Deal, Morton Plant Hospital
Pierre de Villiers, Cleveland Clinic Foundation
Luis Dibos, Union Memorial Hospital
Joseph Diliberto, Diagnostic Clinical Research
Francis X. Downey, St Luke’s Medical Center
Mercedes Dullum, Washington Adventist
Michael P. Eaton, University of Rochester Medical Center
Fred Edwards, University of Florida Health Science Center, Jack-
sonville
Jack Julian Farahi, BreakThru Clinical Trials
John E. Fetter, St Mary’s-Duluth Clinic
Jane Fitch, Baylor College of Medicine
Stanley A. Gall, St John’s Hospital
Deepak Gangahar, Giles S. Hedderic, Nebraska Heart Institute
Michael Goldberg, Cooper Hospital UMC
Steven Goldman, Janice Christensen, Bruce Toporoff, Veteran
Affairs Medical Center
L. Michael Graver, Long Island Jewish Medical Center
Michael Griffin, Yale University
Charles Hantler, University of Texas Health Sciences Center at
San Antonio
Charles Hogue, Thoralf Sundt, Washington University School of
Medicine
Ronald P. Karlsburg, Brotman Medical Center
Irving Kron, University of Virginia Health Science Center
Irvin Krukenkamp, Stony Brook Hospital
John H. Lemmer, Legacy Good Samaritan Hospital
Jerrold Levy, VA-Atlanta
Ted Lillehei, United Hospital
Stephen Lincoln, St Joseph’s Medical Center
Stephen Longo, Pennsylvania State College of Medicine-M.S.
Hershey Medical Center
John Luber, Gilbert Johnston, St Joseph Medical
Jose Marquez, Allegheny General Hospital
Joseph P. Matthew, Andrew Hilton, Duke University Medical
Center
Imran Niazi, St Francis Hospital
Nancy Nussmeier, Prashant Lotlikar, Texas Heart Institute
Dennis Pupello, Robert Goldstein, Florida West Coast Clinical
Research Group
James G. Ramsay, Emory University Hospital
Jay Requarth, Camcare Health Education and Research Institute
Jeffrey B. Rich, Sentara Norfolk General Hospital
Michael Rosenbloom, Memorial Regional, Hollywood, FL
Mark Sand, Definitive Health Services
Stanton K. Shernan, Brigham and Women’s Hospital
Christopher Stone, Kenosha Hospital and Medical Center
John Streitz, St Luke’s Hospital
Victor Tedesco, Touro Infirmary Center
James Todd, Peninsular Regional Medical Center
Melvin J. Tonkon, Anaheim Memorial
Clifford van Meter, Ochsner Foundation
Russell Vester, Lindner Center for Cardiovascular Research
Arthur Wallace, San Francisco VA Medical Center
Gary Yurow, Dale Senior, Jewish Hospital, KY
Robert Zeff, Iowa Heart Center
Kenton Zehr, Mayo Clinic
306.e2 The Journal of Thoracic and Cardiovascular Surgery ● February 2005
